CGTX logo

Cognition Therapeutics, Inc.

CGTX
Healthcare|Biotechnology|US
$0.69
+0.05 (+8.12%)
DCF Value
$0.60
Tangible Book / Share
$0.31
Cash / Share
$0.32
Next Earnings Report
Mar 25, 2027
EPS est. -$0.14
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Dec 18, 2025 (S-3). Possible dilution.

Upcoming Data Readouts (13)

Mar 2027
Est. completion
NARett Syndrome
Technology-supported Motor Rehabilitation for People With Rett Syndrome
NCT07418905n=14
Apr 2027
Est. completion
P4Alzheimer Disease
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
NCT07633470n=150
May 2027
Est. completion
P2Early Alzheimer's Disease
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
NCT05531656n=540
Jun 2027
Est. completion
NADiabetic Peripheral Neuropathy
Innovative Multi-Variable Biofeedback for Improving Gait Performance in Individuals With Diabetic Peripheral Neuropathy
NCT06591780n=25
Jul 2027
Est. completion
NAMultiple Sclerosis
Enhancing Self-Esteem in Patients With Multiple Sclerosis: A Randomised Controlled Trial of the Lexical Association Technique
NCT07064291n=160
Aug 2027
Est. completion
NADiabetic Peripheral Neuropathy
Walking Function in Diabetic Peripheral Neuropathy
NCT05965336n=50
Dec 2027
Est. completion
Language Development
Cortical Tracking of Speech in the First Year of Life
NCT07531706n=50
Dec 2027
Est. completion
Frontotemporal Dementia, Behavioral Variant
Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative Diseases
NCT07531732n=34
Dec 2027
Est. completion
NAMental Fatigue
Acute Mental Fatigue and Muscle Strength
NCT07846618n=50
Feb 2028
Est. completion
P3Psychosis
Stratification and Treatment in Early Psychosis Study - ENHANCE
NCT06778564n=250
Apr 2028
Est. completion
NAAnorexia Nervosa
Influence of Control Deprivation on the Use of the Analytical Cognitive Style in Anorexic Subjects
NCT07274722n=54
Jul 2028
Est. completion
NAAging
Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)
NCT06507189n=250
Apr 2030
Est. completion
NAEpilepsy
Contribution of Fast-ripples to the Improvement of the Neurosurgical Management of Drug-refractory Epilepsy
NCT06105645n=440

Recent Press Releases

Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
Nov 5, 2026 · GlobeNewsWire
Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
Nov 2, 2026 · GlobeNewsWire
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
Oct 22, 2026 · GlobeNewsWire
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
Oct 13, 2026 · GlobeNewsWire
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
Sep 29, 2026 · GlobeNewsWire
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
Sep 8, 2026 · GlobeNewsWire

SEC Filings (52)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 202610-QQuarterly reportDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Oct 22, 20268-KMaterial eventDocumentIndex
Aug 7, 202610-QQuarterly reportDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jun 24, 20268-KMaterial eventDocumentIndex
Jun 18, 20268-KMaterial eventDocumentIndex
Jun 4, 20268-KMaterial eventDocumentIndex
May 21, 20268-KMaterial eventDocumentIndex
May 8, 202610-QQuarterly reportDocumentIndex
May 7, 20268-KMaterial eventDocumentIndex
Apr 27, 2026ARSAnnual report to holdersDocumentIndex
Apr 27, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 27, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 26, 2026S-8Employee stock planDocumentIndex
Mar 26, 202610-KAnnual reportDocumentIndex
Mar 26, 20268-KMaterial eventDocumentIndex
Mar 2, 20268-KMaterial eventDocumentIndex
Jan 27, 20268-KMaterial eventDocumentIndex
Dec 23, 2025EFFECTDocumentIndex
Dec 18, 20258-KMaterial eventDocumentIndex
Dec 18, 2025S-3Shelf registrationDocumentIndex
Nov 6, 202510-QQuarterly reportDocumentIndex
Nov 6, 20258-KMaterial eventDocumentIndex
Sep 23, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Sep 15, 20258-KMaterial eventDocumentIndex
Aug 28, 20258-KMaterial eventDocumentIndex
Aug 28, 2025424B5Offering prospectusDocumentIndex
Aug 26, 20258-KMaterial eventDocumentIndex
Aug 7, 20258-KMaterial eventDocumentIndex
Aug 7, 202510-QQuarterly reportDocumentIndex
Jun 20, 20258-KMaterial eventDocumentIndex
Jun 3, 20258-KMaterial eventDocumentIndex
Jun 2, 20258-KMaterial eventDocumentIndex
May 8, 20258-KMaterial eventDocumentIndex
May 7, 202510-QQuarterly reportDocumentIndex
May 7, 20258-KMaterial eventDocumentIndex
Apr 28, 2025ARSAnnual report to holdersDocumentIndex
Apr 28, 2025DEFA14AProxy / shareholder voteDocumentIndex
Apr 28, 2025DEF 14AProxy / shareholder voteDocumentIndex